Emerging drugs in sepsis

Bibliography

• Dellinger RP, Levy MM, Carlet JM, Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock. Crit Care Med 2008;36:296-327
   PubMed Web of Science ®Google Scholar
• Toltl LJ, Swystun LL, Pepler L, Liaw PC. Protective effects of activated protein C in sepsis. Thromb Haemost 2008;100:582-92
   PubMed Web of Science ®Google Scholar
• Houston G, Cuthbertson BH. Activated protein C for the treatment of severe sepsis. Clin Microbiol Infect 2009;15:319-24
   PubMed Web of Science ®Google Scholar
• Hodgin KE, Moss M. The epidemiology of sepsis. Curr Pharm Des 2008;14:1833-9
   PubMed Web of Science ®Google Scholar
• Ferrer R, Artigas A, Suarez D, Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med 2009;180:861-6
   PubMed Web of Science ®Google Scholar
• Kumar A, Haery C, Paladugu B, The duration of hypotension before the initiation of antibiotic treatment is a critical determinant of survival in a murine model of Escherichia coli septic shock: association with serum lactate and inflammatory cytokine levels. J Infect Dis 2006;193:251-8
   PubMed Web of Science ®Google Scholar
• Garcin F, Leone M, Antonini F, Non-adherence to guidelines: an avoidable cause of failure of empirical antimicrobial therapy in the presence of difficult-to-treat bacteria. Intensive Care Med 2009; doi: 10.1007/s00134-009-1660-8
   Google Scholar
• Kollef KE, Schramm GE, Wills AR, Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest 2008;134:281-7
   PubMed Web of Science ®Google Scholar
• Leone M, Martin C. How to break the vicious circle of antibiotic resistances? Curr Opin Crit Care 2008;14:587-92
   PubMed Web of Science ®Google Scholar
• Paterson DL, Depestel DD. Doripenem. Clin Infect Dis 2009;49:291-8
   PubMed Web of Science ®Google Scholar
• Kattan JN, Villegas MV, Quinn JP. New developments in carbapenems. Clin Microbiol Infect 2008;14:1102-11
   PubMed Web of Science ®Google Scholar
• Chastre J, Wunderink R, Prokocimer P, Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008;36:1089-96
   PubMed Web of Science ®Google Scholar
• El Solh AA, Alhajhusain A. Update on the treatment of Pseudomonas aeruginosa pneumonia. J Antimicrob Chemother 2009;64:229-38
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Wiebe R, Dilay L, Comparative review of the carbapenems. Drugs 2007;67:1027-52
   PubMed Web of Science ®Google Scholar
• Leone M, Garcin F, Bouvenot J, Ventilator-associated pneumonia: breaking the vicious circle of antibiotic overuse. Crit Care Med 2007;35:379-85
   PubMed Web of Science ®Google Scholar
• Jaksic B, Martinelli G, Perez-Oteyza J, Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 2006;42:597-607
   PubMed Web of Science ®Google Scholar
• Wilcox MH, Tack KJ, Bouza E, Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis 2009;48:203-12
   PubMed Web of Science ®Google Scholar
• De Cock E, Krueger WA, Sorensen S, Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany. Infection 2009;37:123-32
   PubMed Web of Science ®Google Scholar
• Schürmann D, Sorensen SV, De Cock E, Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany. Eur J Health Econ 2009;10:65-79
   PubMed Web of Science ®Google Scholar
• Bounthavong M, Hsu DI, Okamoto MP. Cost-effectiveness analysis of linezolid vs. vancomycin in treating methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model. Int J Clin Pract 2009;63:376-86
   PubMed Web of Science ®Google Scholar
• El Solh A. Ceftobiprole: a new broad spectrum cephalosporin. Expert Opin Pharmacother 2009;10:1675-86
   PubMed Web of Science ®Google Scholar
• Leonard SN, Cheung CM, Rybak MJ. Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008;52:2974-6
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Sniezek G, Schweizer F, Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus. Drugs 2009;69:809-31
   PubMed Web of Science ®Google Scholar
• Talbot GH, Thye D, Das A, Ge Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007;51:3612-16
   PubMed Web of Science ®Google Scholar
• McGee L, Biek D, Ge Y, In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2009;53:552-6
   PubMed Web of Science ®Google Scholar
• Morrissey I, Ge Y, Janes R. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia. Int J Antimicrob Agents 2009;33:515-19
   PubMed Web of Science ®Google Scholar
• Nicolau DP. Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline. Expert Opin Pharmacother 2009;10:1213-22
   PubMed Web of Science ®Google Scholar
• Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect 2008;56:432-6
   PubMed Web of Science ®Google Scholar
• Markou N, Markantonis SL, Dimitrakis E, Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther 2008;30:143-51
   PubMed Web of Science ®Google Scholar
• Plachouras D, Karvanen M, Friberg LE, Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009;53:3430-6
   PubMed Web of Science ®Google Scholar
• Falagas ME, Siempos II, Rafailidis PI, Inhaled colistin as monotherapy for multidrug-resistant gram (-) nosocomial pneumonia: a case series. Respir Med 2009;103:707-13
   PubMed Web of Science ®Google Scholar
• Cruz DN, Perazella MA, Bellomo R, Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care 2007;11:R47
   PubMed Web of Science ®Google Scholar
• Cruz DN, Antonelli M, Fumagalli R, Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009;301:2445-52
   PubMed Web of Science ®Google Scholar
• Dyson A, Singer M. Animal models of sepsis: why does preclinical efficacy fail to translate to the clinical setting? Crit Care Med 2009;37:S30-37
   PubMed Web of Science ®Google Scholar
• Dellinger RP, Tomayko JF, Angus DC, Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial. Crit Care Med 2009;37:2929-38
   PubMedGoogle Scholar
• Rivers EP, Coba V, Whitmill M. Early goal-directed therapy in severe sepsis and septic shock: a contemporary review of the literature. Curr Opin Anaesthesiol 2008;21:128-40
   PubMed Web of Science ®Google Scholar
• McDunn JE, Husain KD, Polpitiya AD, Plasticity of the systemic inflammatory response to acute infection during critical illness: development of the riboleukogram. PLoS ONE 2008;3:e1564
   PubMed Web of Science ®Google Scholar
• Poli-de-Figueiredo LF, Garrido AG, Nakagawa N, Sannomiya P. Experimental models of sepsis and their clinical relevance. Shock 2008;30(Suppl 1):53-9
   PubMed Web of Science ®Google Scholar
• Texereau J, Pene F, Chiche J, Importance of hemostatic gene polymorphisms for susceptibility to and outcome of severe sepsis. Crit Care Med 2004;32:S313-19
   PubMed Web of Science ®Google Scholar
• Pachot A, Monneret G, Brion A, Messenger RNA expression of major histocompatibility complex class II genes in whole blood from septic shock patients. Crit Care Med 2005;33:31-8
   PubMed Web of Science ®Google Scholar
• Meisel C, Schefold JC, Pschowski R, Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009;180:640-8
   PubMed Web of Science ®Google Scholar
• Stephens DP, Thomas JH, Higgins A, Randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor in patients with septic shock. Crit Care Med 2008;36:448-54
   PubMedGoogle Scholar
• Annane D, Sébille V, Charpentier C, Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-71
   PubMed Web of Science ®Google Scholar
• Sprung CL, Annane D, Keh D, Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111-24
   PubMed Web of Science ®Google Scholar
• Bernard GR, Vincent JL, Laterre PF, Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709
   PubMed Web of Science ®Google Scholar
• Abraham E, Laterre P, Garg R, Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005;353:1332-41
   PubMed Web of Science ®Google Scholar
• Bernard GR, Margolis BD, Shanies HM, Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest 2004;125:2206-16
   PubMed Web of Science ®Google Scholar
• Messaris E, Betrosian A, Memos N, Administration of human protein C improves survival in an experimental model of sepsis. Crit Care Med 2009. [Epub ahead of print]
   Google Scholar
• Wang Z, Su F, Rogiers P, Vincent J. Beneficial effects of recombinant human activated protein C in a ewe model of septic shock. Crit Care Med 2007;35:2594-600
   PubMed Web of Science ®Google Scholar
• Sanchez B, Piacentini E, Pradella V, Hemodynamic effects of recombinant human activated protein C in patients with septic shock. J Crit Care 2009; doi:10.1016/j.jcrc.2009.06.046
   Google Scholar
• Monnet X, Lamia B, Anguel N, Rapid and beneficial hemodynamic effects of activated protein C in septic shock patients. Intensive Care Med 2005;31:1573-6
   PubMed Web of Science ®Google Scholar
• Jaimes F, De La Rosa G, Morales C, Unfractioned heparin for treatment of sepsis: a randomized clinical trial (The HETRASE Study). Crit Care Med 2009;37:1185-96
   PubMed Web of Science ®Google Scholar
• Muto Y, Suzuki K, Iida H, EF6265, a novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor, protects against sepsis-induced organ dysfunction in rats. Crit Care Med 2009;37:1744-9
   PubMed Web of Science ®Google Scholar
• Iba T, Takayama T. Enoxaparin attenuates endothelial damage with less bleeding compared with unfractionated heparin in endotoxemic rats. Shock 2009;32:530-4
   Google Scholar
• Kopterides P, Falagas ME. Statins for sepsis: a critical and updated review. Clin Microbiol Infect 2009;15:325-34
   PubMed Web of Science ®Google Scholar
• Tleyjeh IM, Kashour T, Hakim FA, Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 2009;169:1658-67
   PubMed Web of Science ®Google Scholar
• Thomsen RW, Riis A, Kornum JB, Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients. Arch Intern Med 2008;168:2081-7
   PubMed Web of Science ®Google Scholar
• Donnino MW, Cocchi MN, Howell M, Statin therapy is associated with decreased mortality in patients with infection. Acad Emerg Med 2009;16:230-4
   PubMed Web of Science ®Google Scholar
• Dobesh PP, Klepser DG, McGuire TR, Reduction in mortality associated with statin therapy in patients with severe sepsis. Pharmacotherapy 2009;29:621-30
   PubMed Web of Science ®Google Scholar
• Novack V, Eisinger M, Frenkel A, The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double-blind placebo controlled clinical trial. Intensive Care Med 2009;35:1255-60
   PubMed Web of Science ®Google Scholar
• Marik PE, Kaplan D. Aspiration pneumonia and dysphagia in the elderly. Chest 2003;124:328-36
   PubMed Web of Science ®Google Scholar
• Okaishi K, Morimoto S, Fukuo K, Reduction of risk of pneumonia associated with use of angiotensin I converting enzyme inhibitors in elderly inpatients. Am J Hypertens 1999;12:778-83
   PubMed Web of Science ®Google Scholar
• Hagiwara S, Iwasaka H, Matumoto S, Effects of an angiotensin-converting enzyme inhibitor on the inflammatory response in in vivo and in vitro models. Crit Care Med 2009;37:626-33
   PubMed Web of Science ®Google Scholar
• Rafailidis PI, Matthaiou DK, Varbobitis I, Falagas ME. Use of ACE inhibitors and risk of community-acquired pneumonia: a review. Eur J Clin Pharmacol 2008;64:565-73
   PubMed Web of Science ®Google Scholar
• Cogulu O, Onay H, Uzunkaya D, Role of angiotensin-converting enzyme gene polymorphisms in children with sepsis and septic shock. Pediatr Int 2008;50:477-80
   PubMed Web of Science ®Google Scholar
• Shimizu F, Kasai T, Takamata A. Involvement of central angiotensin II type 1 receptors in LPS-induced systemic vasopressin release and blood pressure regulation in rats. J Appl Physiol 2009;106:1943-8
   PubMed Web of Science ®Google Scholar
• Yao S, Feng D, Wu Q, Losartan attenuates ventilator-induced lung injury. J Surg Res 2008;145:25-32
   PubMed Web of Science ®Google Scholar
• Jerng J, Hsu Y, Wu H, Role of the renin-angiotensin system in ventilator-induced lung injury: an in vivo study in a rat model. Thorax 2007;62:527-35
   PubMed Web of Science ®Google Scholar
• Shen L, Mo H, Cai L, Losartan prevents sepsis-induced acute lung injury and decreases activation of nuclear factor kappaB and mitogen-activated protein kinases. Shock 2009;31:500-6
   PubMed Web of Science ®Google Scholar
• Mortensen EM, Restrepo MI, Copeland LA, Impact of previous statin and angiotensin II receptor blocker use on mortality in patients hospitalized with sepsis. Pharmacotherapy 2007;27:1619-26
   PubMed Web of Science ®Google Scholar
• Szelényi J, Vizi ES. The catecholamine cytokine balance: interaction between the brain and the immune system. Ann NY Acad Sci 2007;1113:311-24
   PubMed Web of Science ®Google Scholar
• Ackland GL, Yao ST, Rudiger A, Cardioprotection, attenuated systemic inflammation, and survival benefit of beta1-adrenoceptor blockade in severe sepsis in rats. Crit Care Med 2009 [Epub ahead of print]
   Google Scholar
• Lang CH, Nystrom G, Frost RA. Beta-adrenergic blockade exacerbates sepsis-induced changes in tumor necrosis factor alpha and interleukin-6 in skeletal muscle and is associated with impaired translation initiation. J Trauma 2008;64:477-86
   PubMed Web of Science ®Google Scholar
• Nakamura A, Niimi R, Yanagawa Y. Protection from sepsis-induced acute renal failure by adenoviral-mediated gene transfer of {beta} 2-adrenoceptor. Nephrol Dial Transplant 2009. [Epub ahead of print]
   Google Scholar
• Rough J, Engdahl R, Opperman K, beta2 Adrenoreceptor blockade attenuates the hyperinflammatory response induced by traumatic injury. Surgery 2009;145:235-42
   PubMed Web of Science ®Google Scholar
• Gutierrez J, Hossam A, Lazarezcu R, Effect of beta blockers on sepsis outcome. Med Sci Monit 2009;15:CR499-503
   PubMed Web of Science ®Google Scholar
• Schmittinger CA, Dünser MW, Haller M, Combined milrinone and enteral metoprolol therapy in patients with septic myocardial depression. Crit Care 2008;12:R99
   PubMed Web of Science ®Google Scholar
• Levy RM, Mollen KP, Prince JM, Systemic inflammation and remote organ injury following trauma require HMGB1. Am J Physiol Regul Integr Comp Physiol 2007;293:R1538-44
   PubMed Web of Science ®Google Scholar
• Yang H, Ochani M, Li J, Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004;101:296-301
   PubMed Web of Science ®Google Scholar
• Cordido F, Isidro ML, Nemiña R, Sangiao-Alvarellos S. Ghrelin and growth hormone secretagogues, physiological and pharmacological aspect. Curr Drug Discov Technol 2009;6:34-42
   PubMedGoogle Scholar
• Chorny A, Anderson P, Gonzalez-Rey E, Delgado M. Ghrelin protects against experimental sepsis by inhibiting high-mobility group box 1 release and by killing bacteria. J Immunol 2008;180:8369-77
   PubMed Web of Science ®Google Scholar
• Martin C, Leone M, Viviand X, High adenosine plasma concentration as a prognostic index for outcome in patients with septic shock. Crit Care Med 2000;28:3198-202
   PubMed Web of Science ®Google Scholar
• Gallos G, Ruyle TD, Emala CW, Lee HT. A1 adenosine receptor knockout mice exhibit increased mortality, renal dysfunction, and hepatic injury in murine septic peritonitis. Am J Physiol Renal Physiol 2005;289:F369-76
   PubMed Web of Science ®Google Scholar
• Lee HT, Kim M, Joo JD, A3 adenosine receptor activation decreases mortality and renal and hepatic injury in murine septic peritonitis. Am J Physiol Regul Integr Comp Physiol 2006;291:R959-69
   PubMed Web of Science ®Google Scholar
• Singer M. Cellular dysfunction in sepsis. Clin Chest Med 2008;29:655-60, viii-ix
   PubMed Web of Science ®Google Scholar
• Bayir H, Kagan VE. Bench-to-bedside review: mitochondrial injury, oxidative stress and apoptosis–there is nothing more practical than a good theory. Crit Care 2008;12:206
   PubMed Web of Science ®Google Scholar
• Yasuhara S, Asai A, Sahani ND, Martyn JAJ. Mitochondria, endoplasmic reticulum, and alternative pathways of cell death in critical illness. Crit Care Med 2007;35:S488-95
   PubMed Web of Science ®Google Scholar
• Supinski GS, Murphy MP, Callahan LA. MitoQ administration prevents endotoxin-induced cardiac dysfunction. Am J Physiol Regul Integr Comp Physiol 2009;297:R1095-102
   PubMed Web of Science ®Google Scholar
• Gerö D, Szabó C. Poly(ADP-ribose) polymerase: a new therapeutic target? Curr Opin Anaesthesiol 2008;21:111-21
   PubMed Web of Science ®Google Scholar
• Rinaldi S, Landucci F, De Gaudio AR. Antioxidant therapy in critically septic patients. Curr Drug Targets 2009;10:872-80
   PubMed Web of Science ®Google Scholar
• Vincent J, Forceville X. Critically elucidating the role of selenium. Curr Opin Anaesthesiol 2008;21:148-54
   PubMed Web of Science ®Google Scholar
• van der Poll T, Opal SM. Host-pathogen interactions in sepsis. Lancet Infect Dis 2008;8:32-43
   PubMed Web of Science ®Google Scholar
• Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138-50
   PubMed Web of Science ®Google Scholar
• Munoz C, Carlet J, Fitting C, Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 1991;88:1747-54
   PubMed Web of Science ®Google Scholar
• Luyt C, Combes A, Deback C, Herpes simplex virus lung infection in patients undergoing prolonged mechanical ventilation. Am J Respir Crit Care Med 2007;175:935-42
   PubMed Web of Science ®Google Scholar
• Limaye AP, Kirby KA, Rubenfeld GD, Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 2008;300:413-22
   PubMed Web of Science ®Google Scholar
• Tidswell M, Tillis W, Larosa S, Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med 2009. [Epub ahead of print]
   Google Scholar
• Rice TW, Wheeler AP, Morris PE, Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis. Crit Care Med 2006;34:2271-81
   PubMed Web of Science ®Google Scholar
• Leibovici L. Non-antibiotic treatment for bacterial infections: how to validate chance findings. Clin Microbiol Infect 2009;15:298-301
   PubMed Web of Science ®Google Scholar